Dalteparin: over 20 years of clinical experience
2008 (English)In: EJHP Practice, ISSN 1781-9989, Vol. 14, no 2, 38-44 p.Article in journal (Refereed) Published
Dalteparin was one of the first low molecular weight heparins (LMWHs) to be used in clinical practice, and was initially available for the prevention of venous thromboembolic disease and for haemodialysis. In more than two decades of clinical use, extensive clinical studies have evaluated the role of dalteparin in a wide range of therapeutic areas. These include: the prevention of venous thromboembolism (VTE) in surgical patients (general surgery, surgery for abdominal/pelvic cancers, high-risk orthopaedic surgery) and in acutely ill medical patients; the prevention of recurrent VTE in patients with cancer; and the management of acute coronary syndromes (ACS). This article provides an update on the range of clinical indications for dalteparin, and the findings of relevant clinical trials.
Place, publisher, year, edition, pages
2008. Vol. 14, no 2, 38-44 p.
dalteparin, heparin, low molecular weight heparin (LMWH), thromboprophylaxis
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-152204ISI: 000259638600021OAI: oai:DiVA.org:uu-152204DiVA: diva2:412975